Our work has defined the mechanisms of action of a previously unappreciated estrogen receptor known as GPR30/GPER-1. We have shown that primary breast tumors that retain GPER-1 predict disease progression, a relationship diametrically opposed from ER. We are addressing the association of GPER-1 and tumor relapse in patients treated with aromatase inhibitors or tamoxifen. This work may reshape our view regarding the appropriate assignment of endocrine therapy for patients with breast cancer.
Edward Filardo is a molecular endocrinologist whose current research focuses on rapid actions of estrogen. He received degrees in Microbiology from the University of California at Los Angeles (BS) and from the University of Texas Southwestern Medical School (PhD). He came to Brown after completing a postdoctoral fellowship at the Scripps Research Institute in which he characterized functional motifs within integrins that promote tumor cell adhesion and metastasis. His research group has identified and characterized a plasma membrane-associated estrogen receptor, formerly known as GPR30, that functions independently from the estrogen receptor, ER. His research group has shown that GPER-1 triggers rapid estrogen signals, including the release of membrane-tethered EGF ligands from the surface of human breast cancer cells. He is an American Cancer Society Research Scholar.
EDWARD FILARDO, PhD
Collaborators at other institutions:
Are you Edward Filardo? Click here to edit your research profile.